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About 40% of HNSCC cases arise in the oral cavity and oropharynx (oral squamous cell carcinoma [OSCC] ). 2 In the United States, patients with OSCC have a 5-year survival of 50% to 60%. 3 Those patients who survive often suffer disfigurement, loss of eating and speech function, and poor quality of life. 4 Prediction of progression of HNSCC can have an important bearing on the aggressiveness of treatment of HNSCC. However, tumor characteristics such as anatomic site, thickness, and grade are limited in their ability to predict prognosis and treatment response. 5 HNSCC likely results from cumulative epigenetic and genetic alterations. [5] [6] [7] [8] [9] [10] [11] Genetic alterations, including copy number variation (CNVcopy number gains or losses) and loss of hetero-zygosity (LOH-allelic imbalance or copy-neutral LOH), may result in inactivation of tumor-suppressor genes and activation of oncogenes, 8, 12, 13 which in turn may lead to uncontrolled cell growth and metastasis. [12] [13] [14] [15] [16] Plausibly, the presence of CNV/LOH has the potential to serve as a prognostic indicator, alone or in combination with other markers, to identify HNSCC patients at high risk of recurrence and death. The purpose of this review is to summarize current knowledge with regard to CNV and LOH as they are related to the prognosis of HNSCC.
METHODS
For this review, we searched PubMed using the following keys words from MeSH database: ' [Mesh] and SNP arrays] to check whether there were any additional reports on genomic aberrations and survival/recurrence that used high throughput array methods.
RESULTS
We grouped the studies conducted over the past decades into 2 categories based on the methodologies used in each of the studies: low throughput/ low resolution methods (fluorescence in situ hybridization [FISH] and polymerase chain reaction [PCR]-related methods) to study localized CNV/LOH occurrence; and high throughput/high resolution methods (array-related methods) to identify genome-wide CNV/LOH events. Tables 1  and 2 describe respectively the association between CNV/LOH and HNSCC survival by low throughput methods (Table 1) and high throughput methods (Table 2) . 17 located in this region were associated with shorter survival. It is possible that amplification of 11q13 plays an important role in head and neck cancer survival, given the many known oncogenes, such as bcl-1, Int-2, hst-1, EMS1, CCND1/PRAD1, reside in this region. 8 An increase in the copy number at 3q26-27, 29 CCNL1 (3q25-q29), 30 EGFR (7p12), 31, 32 BTAK (20q13) and E2F1 (20q11) 33 ; increased c-MYC/CDKN2A (8q24.21/9p21) and CCND1/CDKN2A (11q13/ 9p21) ratios, 28 combination of CCND1 amplification and p16 (CDKN2A, 9p21) deletion, 23 and loss of DIAI (22q13) 34 have also been shown to beassociated with reduced head and neck cancer survival.
Results from close to 2 dozen studies indicate that many of the LOH events on certain chromosomal regions are associated with shorter survival of HNSCC patients ( However, some studies reported that such an association was only seen if LOH changes were detected in more than 1 or 2 chromosomal regions While informative, there are some limitations to the above mentioned studies. The specimens from some of these studies were from formalinfixed, paraffin-embedded tissues, which could have led to problems with DNA being fragmented or degraded. 17, 20, 21, 23, 24, 27, [29] [30] [31] 36, 39, 41, 42, 47, 53 Samples with mixed population of cells will have attenuated signals. Some of these studies used microdissection to collect purer cell populations to avoid signal contamination caused by bystander cell populations, 25 35, 38 Most of these studies focused on a few individual genes or microsatellite markers (range, 1-55) located in quite limited regions of chromosomal arms or cytobands and were conducted by PCRbased methods, FISH, or Southern Blot methods that were not very sensitive. 17, 18, 22, 29, 34, 48 The pros and cons of various methods used to detect CNV and LOH have been summarized by Wreesmann and Singh. 7 In general, whole genomebased detection methods, such as comparative genome hybridization (CGH) and single nucleotide polymorphism (SNP) arrays will provide broader coverage of the chromosomal aberrations with more detailed profiling. 7, 54, 55 Genome-Wide Copy Number Variation and Loss of Heterozygosity and Survival. By using CGH, studies have identified some CNV and LOH that were associated with poor prognosis of HNSCC (Table  2 ). In OSCC, 7p gains were associated with worse survival. 56 In HNSCC, poor prognosis was associated with gains at 2q12, 3q21-29, 3q25-27, 6p21.1, 8p11, 11q13, 12q24, 14q11, 14q23, 14q24, 14q31, 14q32, 15q24, 16q22, 17q23, 17q24, 17q25, 20q13, 22q13; losses at 1p21, 2q34, 5q11, 5q12, 5q14, 5q15, 5q31, 6q14, 6q15, 8p21-22, 10p12, 12q22, 18q11.2, 21p21, 21q11, 21q21, 21q22, 22q [57] [58] [59] ; and high level of gain at 11q13 (ratio >2). 57 In esophageal squamous cell carcinoma, gains at 5p15, 8q24-qter, 14q21, alone or all 3 together, predicted shorter survival. 60 Several of these studies had used fresh frozen tissue with tumor content higher than 70%. [57] [58] [59] One study used microdissected fresh frozen tumor tissues to increase their chances of obtaining high-quality tumor DNA. 60 Gebhart et al 56 53 ; copy number of erbB-2 (17q21.1) >1.2; of erbB-3 (12q13) <0.11 63 ; ratio of c-MYC (8q24.21)/CDKN2A (9p21) >2 28 ; combination of CCND1 (11q13) amplification and CDKN2A (p16, 9p21) deletion 23 ; combination of CCND1 (11q13) amplification and p53 (17p13.1) LOH in patients with stage IV cancer 61 to be associated with higher risk of HNSCC/OSCC recurrence ( Table 3) . Two of these studies applied microdissection to enhance collection of pure cell populations. 25, 62 Another two studies used tissues with tumor content higher than 70%. 28, 53 Other than a few studies that specified the use of fresh frozen tissue, 18, 22, 25, 28 most either did not mention how the tissues were processed 61 or what the tumor content was. [22] [23] [24] 29, 61 . In HNSCC/OSCC, localized LOH changes associated with recurrence were found in the following regions: LOH 2 loci on 2q, 64 ; LOH at p53 (17p13.1) and amplification at CCND1 (11q13) 61 ; LOH/microsatellite instabilities at p53 (17p13.1), INFa (9p22) within tumor margins. 69 A fractional allelic loss score of 0.4, based on 6 SNP markers and 13 microsatellite markers, was associated with OSCC local recurrence. 48 Using fresh frozen tissue with more than 70% tumor content, two CGH studies of HNSCC found the following genomic alterations to be associated with recurrence: gains at 1q32, 1q42-43, 2p24-25, 2q12, 3q21-29, 6p21.1, 6p22-24, 7p22, 11q13,  14q23, 14q24, 14q31, 14q32, 15q24, 16q22, 17q,  20q; losses at 8p21-22, 11q23-25, 18q11.2, 18q21,  19p, 22q ; and high level of gains (ratio >1.5) at 11q13. 58, 59 Compared to the low-throughput methods, these studies had a much improved resolution to detect genome-wide CNV and LOH events. However, CGH still has limited resolution (<5-10 Mb) 7 compared to a new set of SNP arrays with resolution of 15 to 90 kb. 55 Also, unlike the SNP array, CGH can not detect balanced chromosomal changes, such as copy-neutral LOH. 55, 70 SNP Arrays to Detect Genome-Wide Copy Number Variation and Loss of Heterozygosity. SNP arrays were originally designed to assess associations between SNPs and disease risk. However, SNP arrays can also be used as efficient tools to detect CNV and LOH events in cancers by comparing information between tumor and normal reference DNA. 55, [71] [72] [73] To detect LOH, information on SNP genotype from paired tumor and normal DNA was compared to see whether heterozygous loci in the normal reference DNA samples turned into homozygous loci in the tumor DNA samples. To determine CNV, the hybridization signal intensities of corresponding SNP locus in the normal sample and in the tumor sample were compared. 55 72 examined a cell line model for OSCC progression using a 10 K SNP array and suggested that CNV and/or LOH at 3pter-3p35.3, 3p14.1-3p13, 11p, 11q14.3-11q22.2, and 11q13.5-11q14.1 might be associated with OSCC progression. Zhou et al also observed concurrent CNV and LOH in region 1q22-24.1 and 1q42.13 in both premalignant and malignant cells, but not in normal cells. 72 Frequent allelic imbalances, including losses at 3p, 8p, 9p, and gains at 8q, 11q, and 20q, were detected in advanced-stage OSCC samples with the use of 10 K and 100 K SNP arrays. 75 The 500 K Affymetrix SNP array set with 2.5-kb median physical distance and 5.8-kb average distance between SNPs (>85% of genome within 10 kb of a SNP) 76, 77 has been used to simultaneously detect LOH, overall copy number changes and allele-specific copy number changes with very high resolution in various cancers, but not yet in HNSCC. 77 By using a high-resolution array such as the Affymetrix 500 K SNP array set, researchers may discover genomic alterations that contribute to the various clinical phenotypes and varied disease survival. However, while this new technology holds great promise, it also presents some challenges. With the large numbers of genomic aberrations detected by the SNP arrays, concerns about data complexity, multiple-testing issues, and statistical power of the study need to be addressed.
Based on existing cumulative knowledge, survival and recurrence in patients with HNSCC are associated with genomic alterations present in a number of chromosomal regions and genes ( Table  4 ). The most commonly reported CNV associated with survival pertain to chromosomal regions 11q (14 studies), 3q (4 studies), 7p and 22q (3 studies); LOH in 3p (5 studies), 8p and 9p (4 studies), 13q (3 studies). Most of these CNV studies focused on the examinations of specific genes that have been shown to play important roles in head and neck carcinogenesis, eg, CCND1, EMS1, Int-2, bcl-1 at 11q13; CCNL1 at 3q; EGFR at 7p12; or BTAK or E2F1 at 22q. Most LOH studies tested various microsatellite markers at certain regions to analyze the association between LOH changes and survival. As far as recurrence is concerned, the most commonly reported CNV/LOH associated with recurrence involved CNV at 11q (11 studies); LOH at 9p (4 studies) and 17p (3 studies). CNV/ LOH at other chromosomal areas, as listed in Table 4 , has only been reported by 1 or 2 studies. Similar to studies with survival outcomes, these CNV studies with recurrence outcomes focused on some of the specific genes and LOH studies focused on using microsatellite markers.
There were only 2 papers that combined clinical characteristics, such as tumor, node, metastasis (TNM) staging or treatment conditions, with CNV or LOH to predict survival. 37 , 39 Partridge et al found that 3p LOH was associated with poorer survival. The association was present even in patients with early stage I and II tumors. 37 Jamieson et al also showed that in patients who received radiotherapy (RT), 6q LOH was associated with reduced survival. 39 With the advent of SNP array technology and technologies to interrogate transcriptome and proteome, a better picture should emerge regarding the extent CNV/LOH might bear on HNSCC survival and recurrence, the specific CNV and/or LOH that might exert such an effect, and whether certain CNV and/or LOH, alone or in combination with other parameters, such as TNM staging, transcriptome profile, proteome profile, etc, can improve the prediction of HNSCC recurrence and mortality.
CONCLUSIONS
Genomic markers, such as CNV and LOH, have been shown to be associated with disease-specific survival from and recurrence of HNSCC in a number of studies done by low throughput/lower resolution methods. However, most of these studies had some potential limitations, such as poor DNA quality or contaminated signals due to mixed cell populations present in the examined tumor samples. Also, these studies could detect either CNV or LOH, but not both, due to the limitations of their methodology. The current commerciallyavailable SNP arrays have much better resolution than the previously used methods and can be used to simultaneously detect CNV and LOH (allelic imbalance or copy number-neutral LOH). There have been no studies applying the high-resolution SNP arrays, such as the Affymetrix 500 K SNP set, to detect genomic aberrations in HNSCC or to predict HNSCC prognosis. While the SNP array approach provides an opportunity to identify potential genomic markers that could be used to better predict prognosis, there are also a number of challenges researchers need to overcome. These challenges pertain largely to the need for highquality DNA from high tumor content samples in large numbers of patients with HNSCC who have been monitored for tumor recurrence and survival.
